Professionals 250 Users Online

Clinical Trial Kits Market

Market Study on Clinical Trial Kits: Direct-to-Patient Clinical Trials Shaping the Clinical Trial Kits Demand

Clinical Trial Kits Market by Service Type - Kitting Solutions (Drugs Kits | Sample Collection Kits)

Clinical Trial Kits Market Outlook (2022-2032)

The global clinical trial kits market was valued at around US$ 1.3 Bn in 2021. With a projected CAGR of 12.3% for the next ten years; the market is likely to reach a valuation of US$ 4.6 Bn by the end of 2032. The increasing number of clinical trials performed globally is driving the clinical trial kits market.

Report Attributes

Details

Estimated Market Value (2022E)

US$ 1.5 Bn

Forecasted Market Value (2032F)

US$ 4.6 Bn

Global Market Growth Rate (2022-2032)

12.3% CAGR

United States Growth Rate (2022-2032)

13.1% CAGR

Key Companies Covered

  • Azenta Life Sciences
  • Q2 Solutions
  • Patheon
  • LabCorp drug development
  • Charles River Laboratories
  • LabConnect
  • Almac group
  • Precision medicine group
  • Cerba research
  • Alpha Laboratories Ltd
  • Marken SAS
  • Clinigen

Persistence Market Research’s analysis reveals that most of the market revenue is grossed from logistics service-type clinical trial kits. On the other hand, clinical trial kits for phase III will be the most lucrative with an 11.4% of CAGR during 2022 – 2032.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Sales Analysis of Clinical Trial Kits from 2015 to 2021 Vs Market Outlook for 2022 to 2032

The global market for clinical trial kits expanded with a CAGR of 9.9% during 2015-2021. The global clinical trial kits market is expected to create an absolute dollar opportunity of more than US$ 3.2 Bn during 2022-2032.

In 2021, the global market size of clinical trial kits was valued at US$ 1.3 Bn and is estimated to increase to a valuation of US$ 1.5 Bn in 2022. The increasing technological advancement in clinical trials has increased the use of clinical trial kits. Furthermore, the rise in the use of home-based testing has led to further medical research being pursued remotely. As testing is made possible through remote technology and increased adoption, it will help to alleviate doctors' workloads, as is made clear during frequent testing and patient monitoring. Increasing the use of remote testing and considering virtual technologies by professionals is expected to drive the market for medical research.

The global clinical trial kits market is predicted to grow ahead at a CAGR of 12.3% and sales worth US$ 4.6 Bn during 2022 - 2032. The US will continue to be the largest user of clinical trial kits throughout the analysis period accounting for over US$ 1.2 Bn absolute dollar opportunity in the coming 10-year epoch.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

How Direct-to-Patient (DtP) Clinical Trials are going to influence the Clinical Trials Kits Market?

The advantage of DtP clinical trials as they are cost-effective and easy to conduct comparing traditional clinical trials has been motivating the pharmaceuticals and drug manufacturing companies to choose DtP clinical trials. In DtP clinical trials samples are collected from the patient’s home and then transferred to the testing facilities and the drugs are directly delivered to the patient’s home. Quality trial kits are to be used because the damaged trial drugs can have big consequences. The demand for DtP clinical trials is increasing which is propelling the growth of the clinical trial kits market.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Which factors are restraining the growth of the Clinical Trial Kits Market?

The transportation of the samples and medicines with optimum temperature conditions is a key factor in the clinical trials. The proper delivery of the samples to the testing setup and the delivery of the drugs to the right patient at right time is important.

Certain samples and medicines should be needed to preserve at a certain temperature and temperature-controlled shipping containers are more expensive to use than standard shippers are. Another challenge is that the chances of error are high when the individuals do the sample collection. These factors are expected to restrain the growth of the clinical trial kits market.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Regional Insights

How is the demand for Clinical Trial Kits shaping up in North America?

The increasing incidences of cancer have increased the demand for phase III clinical studies in North America. Furthermore, the region's pharmaceutical and drug development companies are shifting to virtual and decentralized clinical trials, which will drive the demand for clinical trial kits in North America over the forecasted years.

Country-Wise Insights

US Clinical Trial Kits Market Analysis

According to Clinical Trials.gov, about 32% of the total registered clinical studies are performed in the US. The rapid adoption of decentralized clinical trials is driving the clinical trial kits market in the US. The clinical trial kits market in the US is expected to reach a valuation of US$ 1.2 Bn by 2032.

China Clinical Trial Kits Market Analysis

The Clinical Trial kits market in China is forecasted to reach a valuation of US$ 381.3 Mn by the end of 2032. China has developed a clinical trial infrastructure with skilled experts and a well-developed network of experienced therapeutic experts. In addition, the large number of the patient pool who are eligible for the clinical trial is also driving the market in China. The clinical trial kits market in China is expected to create an absolute dollar opportunity of US$ 74.8 Mn over the 2022-2032 period.

U.K. Clinical Trial Kits Market Analysis

The market in the U.K. is projected to reach US$ 221 Mn by 2032, growing at a CAGR of 12.8% during the forecast period. The market is expected to gross an absolute dollar opportunity of US$ 56 Mn during 2022 – 2032.

Japan Clinical Trial Kits Market Analysis

In Japan, the market is expected to reach US$ 239 Mn by 2032. Growing at a CAGR of 14% during the forecast period, the market is projected to garner an absolute dollar opportunity of US$ 174 Mn.

Category-Wise Insights

Why Logistics service type is driving the demand for clinical trial kits?

The increasing number of clinical trials performed and the need to transport the samples and medicines without any damage are boosting the growth of this segment. The main function of the logistics in the clinical trial process is to transfer the samples to labs very quickly as possible. The logistics segment accounted for a CAGR of 11.3% during 2015-2021.

How Phase III of clinical trials is driving the clinical trial kits market?

Phase III study of clinical trials includes a large patient population and is conducted in many places at the same time is the key factor driving the market. Phase III studies generally take longer times compared to Phase I and Phase II studies. Phase III studies can detect the side effects of the specific drugs, which passed the phase II, study of the clinical trial. The market through Phase III clinical trials accounted a CAGR of 9.1% during 2015-2021.

Competitive Landscape

At present, clinical trial kit manufacturers are largely actively expanding their manufacturing facilities to boost production. The key companies operating in the clinical trial kits market include Azenta Life Sciences, Q2 Solutions, Patheon (Thermo fisher scientific), LabCorp drug development, Charles River Laboratories, LabConnect, Almac group, Precision medicine group, Cerba research, Alpha Laboratories Ltd, Marken SAS, and Clinigen.

Some of the recent developments by key providers of clinical trial kits are as follows:

  • In May 2022, LabCorp drug development received emergency use authorization from FDA for the first Non-prescription At-Home collection Kit for combined Covid-19, Flu, and RSV detection.
  • In June 2021, UPS's healthcare Clinical trials unit of Marken announced a partnership with THREAD, a decentralized clinical trial technology provider, to create a unified decentralized trial solution in patients’ homes. The partnership between Marken Home Healthcare and Clinical Trial Logistics Services provides a single workflow for patients and clients by having a partnership of Marken's Home Healthcare and Clinical Trial Logistics Services.
  • In June 2021, Daxion Technologies and Q2 Solutions collaborated to develop a new blood test that will help patients to obtain their blood from any location. The new lab test, which works with Tasso's devices, will help patients collect their blood from anywhere.
  • In March 2021, LabConnect announced the expansion of its Johnson City facility to boost the manufacturing of clinical trial kits. The expansion includes the addition of 20,000 square feet to the facility, which will triple the kit building capacity.
  • In January 2021, Almac Diagnostic Services a subsidiary of Almac group enter a strategic partnership with Personal Genome Diagnostics Inc. (PGDx) to improve clinical trial development and companion diagnostic (CDx) projects.
  • In December 2020, Alpha Laboratories Ltd announced the exclusive distribution rights for the UN3373 sample packaging solution in the UK and Ireland to Shuttlepac Ltd.
  • In December 2020, Azenta Life Sciences acquired Trans-Hit Biomarkers Inc. (THB), a global biospecimen procurement and service provider. The extensive capability of THB in collecting biospecimens and clinical samples through a global network of clinical sites and biobanks will help Azenta Life Sciences to strengthen their sample management, biospecimen procurement, and other value-added services to the customers.
  • In June 2020, Marken announced it has started to produce Covid-19 test kits in its Miami facility to expand its supply in US and Canada. The new facility will enable MARKEN to support ongoing Clinical trials and the growing demand for Covid-19 test kits in the US.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies manufacturing clinical trial kits, which is available in the full report.

Key Segments Covered in Clinical Trial Kits Industry Survey

By Service Type:

  • Kitting Solutions
    • Drugs Kits
    • Sample Collection Kits
  • Logistics
    • Transportation
    • Warehousing & Storage
    • Other Logistics

By Phase:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

- Companies Covered in This Report -

  • Azenta Life Sciences
  • Q2 Solutions
  • Patheon (Thermo fisher scientific)
  • LabCorp drug development
  • Charles River Laboratories
  • LabConnect
  • Almac group
  • Precision medicine group
  • Cerba research
  • Alpha Laboratories Ltd
  • Marken SAS
  • Clinigen

- Frequently Asked Questions -

The global clinical trial kits market was valued at US$ 1.3 Bn in 2021.

The global clinical trial kits market is set to witness a high growth rate of 12.3% over the forecasted period and be valued at US$ 4.6 Bn by 2032.

The Clinical Trial Kits Market expanded at a CAGR of 9.9% from 2015 through 2021.

Azenta Life Sciences, Q2 Solutions, Patheon, LabCorp Drug Development, and Charles River Laboratories are the key suppliers of Clinical Trial Kits that are shaping the market.

The US, UK, China, Japan, and South Korea are expected to drive the most sales growth of clinical trial kits.

The market in the US has forecasted to account for over 35% of the global market share in 2032.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate